Paratyphoid fever
disease diseaseOn this page
Also known as paratyphoid fever Aparatyphoid fever Bparatyphoid fever C
Summary
Paratyphoid fever (MONDO:0018626) is a disease and 6 clinical trials. Top therapeutic interventions include typhoid vi polysaccharide vaccine. A subtype of salmonellosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | paratyphoid fever |
| Mondo ID | MONDO:0018626 |
| EFO | EFO:0007420 |
| MeSH | D010284 |
| Orphanet | 443227 |
| DOID | DOID:3055 |
| ICD-11 | 1780040028 |
| NCIT | C34897 |
| SNOMED CT | 51254007 |
| UMLS | C0030528 |
| MedGen | 18303 |
| GARD | 0021855 |
| Is cancer (heuristic) | no |
Also known as: paratyphoid fever A · paratyphoid fever B · paratyphoid fever C
Disease family
This is a subtype of salmonellosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › primary bacterial infectious disease › salmonellosis › paratyphoid fever
Related subtypes (4): typhoid fever, Salmonella gastroenteritis, invasive non-typhoidal salmonellosis, salmonella discitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE4 | 4 |
| Not specified | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00125008 | PHASE4 | COMPLETED | Evaluation of the Vi Polysaccharide Vaccine Against Typhoid Fever |
| NCT00125047 | PHASE4 | COMPLETED | Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood |
| NCT00131820 | PHASE4 | COMPLETED | Introduction of the Vi Polysaccharide Typhoid Vaccine in Hue City, Central Vietnam |
| NCT00131833 | PHASE4 | COMPLETED | Typhoid Vi Vaccine Effectiveness in Hechi, Guangxi, China |
| NCT04878549 | Not specified | RECRUITING | Transcriptomic Responses for the Identification of Pathogens |
| NCT02192008 | Not specified | COMPLETED | Investigating Enteric Fever - Salmonella Typhi and Paratyphi Challenge Study |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| TYPHOID VI POLYSACCHARIDE VACCINE | 3 | 1 |